Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis

References

• Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10(5):56. doi: 10.1038/s41408-020-0323-4.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. doi: 10.1038/leu.2013.313.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi: 10.1200/jco.2005.04.242.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869. doi: 10.1200/jco.2015.61.2267.
   PubMed Web of Science ®Google Scholar
• Paiva B, Paino T, Sayagues J-M, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591–3598. doi: 10.1182/blood-2013-06-510453.
   PubMed Web of Science ®Google Scholar
• van de Donk N. How We manage newly diagnosed multiple myeloma with circulating tumor cells. J Clin Oncol. 2023;41(7):1342–1349. doi: 10.1200/jco.22.02114.
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192. doi: 10.1038/s41408-021-00587-0.
   PubMed Web of Science ®Google Scholar
• An G, Qin X, Acharya C, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol. 2015;94(2):257–264. doi: 10.1007/s00277-014-2211-0.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gertz MA, Lust JA, et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood. 1996;88(5):1780–1787. doi: 10.1182/blood.V88.5.1780.1780.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276–2279. doi: 10.1182/blood-2005-05-1858.
   PubMed Web of Science ®Google Scholar
• Korthals M, Sehnke N, Kronenwett R, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. Biol Blood Marrow Transplant. 2013;19(7):1109–1115. doi: 10.1016/j.bbmt.2013.04.025.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Gupta V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014;28(10):2060–2065. doi: 10.1038/leu.2014.98.
   PubMed Web of Science ®Google Scholar
• Vagnoni D, Travaglini F, Pezzoni V, et al. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics. Br J Haematol. 2015;170(4):523–531. doi: 10.1111/bjh.13484.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Muchtar E, Kumar SK, et al. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica. 2017;102(8):1439–1445. doi: 10.3324/haematol.2017.166629.
   PubMed Web of Science ®Google Scholar
• Abe Y, Narita K, Kobayashi H, et al. Pretreatment (18)F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46(6):1325–1333. doi: 10.1007/s00259-019-4275-5.
   PubMed Web of Science ®Google Scholar
• Han W, Jin Y, Xu M, et al. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma. Hematology. 2021;26(1):510–517. doi: 10.1080/16078454.2021.1948208.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Cai L, Zhang Y, et al. Circulating plasma cells as a biomarker to predict newly diagnosed multiple myeloma prognosis: developing nomogram prognostic models. Front Oncol. 2021;11:639528. doi: 10.3389/fonc.2021.639528.
   PubMedGoogle Scholar
• Galieni P, Travaglini F, Vagnoni D, et al. The detection of circulating plasma cells may improve the revised international staging system (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma. Br J Haematol. 2021;193(3):542–550. doi: 10.1111/bjh.17118.
   PubMed Web of Science ®Google Scholar
• Vasco-Mogorrón MA, Campillo JA, Periago A, et al. Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. Am J Cancer Res. 2021;11:2736–2753.
   PubMed Web of Science ®Google Scholar
• Bertamini L, Oliva S, Rota-Scalabrini D, et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(27):3120–3131. doi: 10.1200/jco.21.01393.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Bezdekova R, Zihala D, et al. More than 2% of circulating tumor plasma cells defines plasma cell Leukemia-Like multiple myeloma. J Clin Oncol. 2023;41(7):1383–1392. doi: 10.1200/jco.22.01226.
   PubMed Web of Science ®Google Scholar
• Xia Y, Shen N, Zhang R, et al. High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics. Front Oncol. 2023;13:1083053. doi: 10.3389/fonc.2023.1083053.
   PubMed Web of Science ®Google Scholar
• Garcés JJ, Cedena MT, Puig N, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol. 2022;40(27):3151–3161. doi: 10.1200/jco.21.01365.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Jevremovic D, Nandakumar B, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol. 2020;95(3):310–315. doi: 10.1002/ajh.25709.
   PubMed Web of Science ®Google Scholar
• Yao W, Yang H, You H, et al. The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients. Front Oncol. 2023;13:1266868. doi: 10.3389/fonc.2023.1266868.
   PubMed Web of Science ®Google Scholar
• Li J, Wang N, Tesfaluul N, et al. Prognostic value of circulating plasma cells in patients with multiple myeloma: a meta-analysis. PLoS One. 2017;12(7):e0181447. doi: 10.1371/journal.pone.0181447.
   PubMed Web of Science ®Google Scholar
• Gláucia FC, Marcos RDS, Tatiani OF, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies 2013.
   Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16. doi: 10.1186/1745-6215-8-16.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815–2834. doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Witzig TE, Pineda AA, et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 1997;19(4):337–342. doi: 10.1038/sj.bmt.1700670.
   PubMed Web of Science ®Google Scholar
• Dingli D, Nowakowski GS, Dispenzieri A, et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood. 2006;107(8):3384–3388. doi: 10.1182/blood-2005-08-3398.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Morice WG, Rajkumar V, et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol. 2014;167(4):500–505. doi: 10.1111/bjh.13067.
   PubMed Web of Science ®Google Scholar
• Bae MH, Park CJ, Kim BH, et al. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma. Cytometry B Clin Cytom. 2018;94(3):493–499. doi: 10.1002/cyto.b.21606.
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Stevenson PA, Libby EN, et al. Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of Post-Transplant maintenance therapy. Biol Blood Marrow Transplant. 2018;24(7):1386–1391. doi: 10.1016/j.bbmt.2018.02.017.
   PubMed Web of Science ®Google Scholar
• Sathya P, Kayal S, Srinivas BH, et al. Quantification of circulating clonal plasma cells by multiparametric flow cytometry as a prognostic marker in patients with newly diagnosed multiple myeloma. Int J Lab Hematol. 2023;45(6):917–926. doi: 10.1111/ijlh.14156.
   PubMed Web of Science ®Google Scholar
• Garcés JJ, San-Miguel J, Paiva B. Biological characterization and clinical relevance of circulating tumor cells: opening the pandora’s box of multiple myeloma. Cancers (Basel). 2022;14(6):1430. doi: 10.3390/cancers14061430.
   PubMed Web of Science ®Google Scholar
• Dutta AK, Alberge JB, Lightbody ED, et al. MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology. Cancer Discov. 2023;13(2):348–363. doi: 10.1158/2159-8290.Cd-22-0482.
   PubMedGoogle Scholar
• Sanoja-Flores L, Flores-Montero J, Puig N, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019;134(24):2218–2222. doi: 10.1182/blood.2019002610.
   PubMed Web of Science ®Google Scholar
• Tembhare PR, Sriram H, Khanka T, et al. Circulating clonal plasma cells at diagnosis and peripheral blood measurable residual disease assessment provide powerful prognostication biomarkers in newly-diagnosed multiple myeloma patients treated without autologous transplant. Blood. 2022;140(Supplement 1):1135–1136. doi: 10.1182/blood-2022-165715.
   Google Scholar
• Sanoja-Flores L, Flores-Montero J, Pérez-Andrés M, et al. Detection of circulating tumor plasma cells in monoclonal gammopathies: methods, pathogenic role, and clinical implications. Cancers (Basel). 2020;12(6):12. doi: 10.3390/cancers12061499.
   Web of Science ®Google Scholar
• Sanoja-Flores L, Flores-Montero J, Garcés JJ, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8(12):117. doi: 10.1038/s41408-018-0153-9.
   PubMedGoogle Scholar
• Mizuta S, Kawata T, Kawabata H, et al. VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era. Int J Hematol. 2019;110(3):322–330. doi: 10.1007/s12185-019-02685-z.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Dispenzieri A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017;31(1):130–135. doi: 10.1038/leu.2016.205.
   PubMed Web of Science ®Google Scholar
• Termini R, Žihala D, Terpos E, et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res. 2022;28(21):4771–4781. doi: 10.1158/1078-0432.Ccr-22-1594.
   PubMed Web of Science ®Google Scholar